Origin treats first patients in study of nitric oxide for diabetic foot ulcers

Origin said today that it treated the 1st patients in its dose-ranging Genesis Phase IIb-equivalent trial. The study is evaluating therapeutic quantities of plasma-generated nitric oxide as a treatment for chronic diabetic foot ulcers. The 27-week trial is slated to enroll up to 100 patients. Patients will be randomized into 1 of 4 dosing regimens, or receive standard of care as a control, to assess the safety and efficacy of plasma-generated nitric oxide, according to Origin. The company plans to treat the participants for 12 weeks and monitor them for 12 weeks following treatment. Get the full story at our sister site, Drug Delivery Business News. The post Origin treats first patients in study of nitric oxide for diabetic foot ulcers appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Diabetes Drug-Device Combinations Wall Street Beat Wound Care Origin Source Type: news